NFE2L2 and vitiligo: Aspirin, simvastatin, and ginsenoside Rk1 can activate Nrf2 and protect melanocytes against oxidative stress damage, suggesting the Nrf2-ARE pathway could be a significant target for vitiligo therapy (33–35).